Vitamin D and Estrogen: What Is the Connection?

Vitamin D and estrogen are locked in a two-way relationship: estrogen ramps up the body’s ability to activate and use vitamin D, while vitamin D helps regulate the production of estrogen itself. This bidirectional loop has real consequences for bone density, immune function, cancer biology, and reproductive health. The connection is well documented in lab, animal, and human studies, though the clinical implications are still being sorted out across several medical specialties.

How Estrogen Boosts Vitamin D Activity

The vitamin D you get from sunlight or a supplement is not immediately useful. It has to be converted in the liver and then again in the kidneys before it becomes the active hormone your cells actually respond to. Estrogen appears to accelerate that second conversion step. In a study of 21 postmenopausal women with osteoporosis, six months of estrogen therapy raised blood levels of the active form of vitamin D from about 24 to 33 pg/mL, while women on placebo saw no change. The researchers concluded that estrogen stimulates the kidney enzyme responsible for this activation, which in turn improves calcium absorption from the gut.¹

Estrogen also appears to increase the expression of the vitamin D receptor itself, the protein that lets cells respond to vitamin D’s signal. Research on autoimmune disease models found that estrogen enhanced vitamin D receptor expression in the inflamed central nervous system, amplifying vitamin D’s anti-inflammatory effects.² In animal studies of depression-like states caused by estrogen withdrawal, both vitamin D and estrogen were shown to upregulate each other’s receptors in the hippocampus, suggesting the partnership operates at a cellular level throughout the body, not just in bone or kidney tissue.³

How Vitamin D Influences Estrogen Production

The reverse direction is just as interesting. Estrogen is made from androgens by an enzyme called aromatase, and vitamin D helps control how much aromatase is produced. In mice genetically engineered to lack the vitamin D receptor, aromatase activity in the ovaries dropped to roughly a quarter of normal levels, and in the testes to about 58% of normal. Even after calcium supplementation brought aromatase activity in the ovaries back up to about 60% of normal, hormone signaling was still abnormal, suggesting vitamin D has a direct role in regulating the aromatase gene that goes beyond just keeping calcium levels steady.⁴

This matters for both sexes. Men also produce small amounts of estrogen through aromatase in the testes and other tissues, and the same study found that vitamin D-receptor-knockout male mice had reduced aromatase and signs of hormonal dysfunction. Supplementing the male mice with estradiol corrected the tissue abnormalities, confirming that the problem stemmed from insufficient estrogen production downstream of vitamin D deficiency.⁵

In the uterus, the picture is consistent. Research on endometrial cells showed that vitamin D at high concentrations increased the expression of aromatase and the estrogen receptor, boosting local estrogen production and promoting the cellular changes needed for embryo implantation. When the vitamin D receptor was knocked down in those same cells, estrogen-related gene expression fell; when it was overexpressed, those markers climbed.⁶

What Happens When Estrogen Drops at Menopause

Menopause is essentially a natural experiment in what happens when one half of this partnership disappears. Estrogen levels plummet, and with them, the body’s ability to activate vitamin D and absorb calcium efficiently. It is no coincidence that vitamin D deficiency is common in postmenopausal women, with estimates suggesting roughly half to four-fifths of this population has insufficient levels. The combined shortfall in both hormones creates a particularly risky environment for bone loss.

Adding vitamin D and calcium supplements alone does not solve everything, though. The Women’s Health Initiative, a large randomized trial, tested calcium and vitamin D supplementation in postmenopausal women and found no improvement in menopause-related symptoms like sleep disturbance, emotional well-being, or fatigue compared to placebo.⁷ That result is a useful reality check: vitamin D is important for bone and immune health, but supplementing it without addressing the estrogen side of the equation does not replicate what the two hormones do together.

Where the combination has shown clearer benefit is in skeletal muscle. A study of middle-aged and elderly women found that vitamin D and estradiol levels were interactively correlated with low skeletal muscle mass, meaning neither one alone predicted muscle health as well as the two in combination. The authors recommended that women at risk for muscle loss consider addressing both hormones rather than focusing on one.⁸

Implications for Breast Cancer

The vitamin D–estrogen relationship takes on a different character in breast tissue. In many breast cancers, estrogen fuels tumor growth by binding to estrogen receptors on cancer cells. Vitamin D appears to counteract this in two ways. First, the active form of vitamin D directly suppresses the gene that codes for the estrogen receptor in breast cancer cells, reducing the receptor’s abundance in a dose-dependent fashion. Lab studies on MCF-7 breast cancer cells showed that vitamin D treatment significantly decreased estrogen receptor gene activity, weakening the cells’ ability to respond to estrogen’s growth signals.⁹

Second, vitamin D reduces the local production of estrogen within breast tumors. In breast cancer cells and the fatty tissue surrounding them, vitamin D suppresses aromatase expression, cutting off the local estrogen supply that feeds the tumor. This happens through direct repression of the aromatase gene and also through reducing prostaglandin E2, a molecule that normally stimulates aromatase activity in breast tissue.¹⁰

A synthetic vitamin D analogue called EB1089 demonstrated this even more dramatically, producing a fourfold reduction in estrogen receptor levels in breast cancer cells compared to untreated controls. The natural form of vitamin D also reduced receptor levels but less sharply.¹¹ Researchers have also explored the molecular pathway by which EB1089 achieves this, finding it works through the vitamin D receptor to pull a specific protein away from the aromatase gene’s promoter region, effectively dialing down aromatase production at the genetic level.¹²

So while vitamin D supports normal estrogen production in healthy tissue, it suppresses estrogen signaling in breast cancer cells. That tissue-specific behavior is what makes the relationship nuanced rather than simply “vitamin D raises estrogen” or “vitamin D lowers estrogen.”

The Immune System and Autoimmune Disease

Some of the most striking evidence for vitamin D–estrogen cooperation comes from autoimmune disease research. Multiple sclerosis, an autoimmune condition that attacks the nervous system, has a female predominance that has grown over recent decades. It is also more common at higher latitudes, where sunlight exposure and vitamin D levels tend to be lower. These two facts led researchers to ask whether estrogen and vitamin D work together to suppress the harmful immune responses behind the disease.

In a key animal experiment, vitamin D prevented an MS-like disease in female mice with normal estrogen levels, but it failed completely in males and in females whose ovaries had been removed. Restoring even low levels of estrogen in the ovariectomized females was enough to bring back vitamin D’s protective effect. The researchers found the synergy works both ways: vitamin D enhanced local estrogen production, while estrogen boosted vitamin D receptor expression in inflamed nervous system tissue.²

Follow-up work clarified one mechanism behind this cooperation. Vitamin D and estrogen together promote the development of regulatory T cells, the immune cells that keep autoimmune responses in check. Estrogen increased these protective cells in a manner that depended on the vitamin D receptor being functional; when the vitamin D pathway was disrupted, estrogen lost this ability.¹³ A review of the broader literature concluded that estrogen’s ability to enhance vitamin D accumulation and receptor expression results in a more potent anti-inflammatory response in females than in males, which may partly explain sex differences in autoimmune disease susceptibility and treatment response.¹⁴

Fertility and Reproductive Outcomes

Because vitamin D influences both aromatase activity and estrogen receptor expression in the uterus, it plays a part in preparing the endometrium for pregnancy. A secondary analysis of data from a multicenter trial in women with polycystic ovary syndrome (PCOS) found that those with blood vitamin D levels above 45 ng/mL had the highest likelihood of live birth after ovulation induction, while levels below 20 ng/mL appeared to impair both the ovulatory response and endometrial receptivity.¹⁵

That said, supplementing vitamin D in women with PCOS has not reliably corrected the metabolic and hormonal problems that characterize the condition. A randomized controlled trial giving vitamin D supplements to PCOS patients raised blood vitamin D levels as expected but showed no significant improvements in most metabolic or endocrine measures, with the exception of a modest drop in blood sugar at one time point during a glucose tolerance test.¹⁶ Vitamin D status clearly matters for reproductive function, but supplementation alone has not been a reliable fix for the hormonal disruptions in PCOS.

Brain Health and Mood After Estrogen Loss

The vitamin D–estrogen partnership extends into the brain. Animal studies modeling menopause by removing the ovaries of rats have shown that both hormones independently reduce neuroinflammation and depressive-like behavior, but combining them produces a stronger effect than either alone. In one experiment, high-dose vitamin D given alongside estradiol produced a marked synergistic antidepressant-like effect, reducing stress hormone levels and increasing self-care behavior more than either treatment individually.¹⁷

At the cellular level, the two hormones upregulate each other’s receptors in the hippocampus and activate a shared anti-inflammatory pathway, reducing molecules that drive brain inflammation after estrogen withdrawal.³ These are animal results, though, and clinical trials have not confirmed that the effect translates straightforwardly to humans. One human trial in elderly postmenopausal women found that neither hormone therapy plus active vitamin D nor the women’s genetic profiles for estrogen and vitamin D receptors predicted improvement in depression scores.¹⁸ The gap between promising animal data and disappointing human trials is a recurring theme in this field.

Combined Therapies for Bone Health

Clinicians have tested whether pairing an estrogen-like drug with vitamin D yields better bone outcomes than either alone. Raloxifene is a selective estrogen receptor modulator commonly prescribed for postmenopausal osteoporosis; it mimics estrogen’s effects on bone without stimulating breast or uterine tissue. In a randomized trial, postmenopausal women with osteopenia who received raloxifene plus vitamin D gained about 2.6% in lumbar spine bone density over 48 weeks, while those on vitamin D alone lost about 0.6%. Similar advantages appeared at the hip and femoral neck.¹⁹

Even the vitamin D levels themselves responded to the pairing. In a separate trial, the combination group’s blood vitamin D rose by an average of about 2.7 ng/mL over 16 weeks, while the raloxifene-only group’s levels actually fell by about 1.7 ng/mL.²⁰ And in an animal model of rotator cuff repair, the combination of raloxifene and vitamin D preserved local bone density and improved tendon-to-bone healing better than either treatment alone.²¹ These results reinforce the idea that vitamin D and estrogen-pathway drugs have complementary mechanisms worth exploiting together.

When Exogenous Estrogen Changes Vitamin D Measurements

If you take estrogen, whether as menopausal hormone therapy or gender-affirming care, it can change how vitamin D looks on a blood test without necessarily changing how much vitamin D your body can use. Estrogen increases production of vitamin D-binding protein, the carrier that shuttles vitamin D around the bloodstream. Higher binding protein means more total vitamin D may be “tied up” rather than free. A study of transgender women taking estradiol found that binding protein increased, but the biologically available fraction of vitamin D did not change meaningfully, whether they used oral or transdermal estradiol.²²

This has a practical implication: if your total vitamin D level looks low while you are taking estrogen, it may partly reflect increased binding protein rather than a true functional deficiency. The free or bioavailable fraction is a more informative measure in people on estrogen therapy, though standard blood panels typically report only total 25-hydroxyvitamin D. It is worth discussing with a clinician if your levels seem lower than expected after starting estrogen.

Phytoestrogens and Vitamin D Metabolism

Plant-derived compounds that mimic estrogen, particularly genistein from soy, can influence vitamin D metabolism in ways that echo what natural estrogen does. In human mammary and prostate cells, genistein boosted the enzyme that activates vitamin D locally and suppressed the enzyme that breaks it down. In a mouse model, soy or genistein feeding had the same effect in colon tissue, and it counteracted the harmful increase in cell proliferation caused by low calcium intake.²³

In colon cancer cell lines, genistein at concentrations achievable through diet reduced the activity of the enzyme that degrades vitamin D and, in one cell type, increased vitamin D receptor expression. Notably, natural estradiol at low concentrations produced similar effects on the vitamin D receptor, supporting the idea that genistein’s action is genuinely estrogenic rather than operating through some unrelated pathway.²⁴ For people who eat soy regularly, these findings hint at one biological route through which dietary phytoestrogens could influence cancer risk, though human intervention trials confirming a direct protective effect are still sparse.

Cardiovascular Overlap

Before menopause, women enjoy lower rates of cardiovascular disease compared to men of the same age, an advantage that narrows sharply after estrogen levels drop. Vitamin D deficiency is independently associated with cardiovascular risk as well, raising the question of whether the two deficiencies compound each other. Researchers have proposed that the negative cardiovascular effects of low vitamin D in postmenopausal women could be improved by combined treatment with vitamin D and sex steroids, pointing to shared pathways involving nitric oxide production and blood vessel relaxation.²⁵ The mechanistic reasoning is sound, but large human trials specifically testing a vitamin D–estrogen combination for heart outcomes have not been completed, so the cardiovascular hypothesis remains earlier in its development than the bone and immune evidence.